Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in VEN-AZA Refractory Acute Myeloid Leukemia
NCT06055621Phase 2Suspended
- Sponsor
- Institut Paoli-Calmettes
- Start
- May 2024
- Primary completion
- Jan 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in acute myeloid leukemia (AML), sponsored by Institut Paoli-Calmettes. Primary endpoint: Tumor Response at 2 months. Started May 2024; status: suspended.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06055621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055621.